Is Cacao A Stimulant? The Methylxanthine Chemistry

Cacao contains two methylxanthine alkaloids, theobromine and caffeine, and methylxanthines are the chemical family that pharmacologists classify as stimulants. So the answer to "is cacao a stimulant" is a chemistry answer rather than an experience one: the compounds are present, they have been measured, and the amounts are published.

What gets written about this online usually skips straight past the measurements to a description of how you will feel. This page stays on the measurements, because those are the part anyone can check.

What is actually in the bean

Theobromine is the dominant methylxanthine in cacao. Sanchez, writing in Foods in 2017, analysed 136 food samples from the Spanish market, 63 of them chocolates and 46 of those dark, using HPLC with diode array detection at 273 nm after AOAC method 980.14 sample preparation. Dark chocolates were grouped by cocoa content into bands below 50%, 50 to 60%, 70 to 75% and 80 to 85%. The reported theobromine range for dark chocolate was 4 to 10 mg per gram, which is 400 to 1,000 mg per 100 g.

Caffeine is the minor partner. The same study found chocolates had the lowest caffeine content of the product categories tested, rising with cocoa percentage. The European Food Safety Authority, in the explanatory document accompanying its 2015 scientific opinion on caffeine, gives an approximate 25 mg of caffeine for a 50 g bar of plain chocolate, against 10 mg for the same weight of milk chocolate, and notes that all such figures are approximate because content varies.

Those two numbers are worth holding next to each other. In dark chocolate, theobromine is present in roughly an order of magnitude more than caffeine. They are different molecules with different pharmacokinetics, and the shorthand that treats chocolate as "a bit like coffee" is a chemical approximation at best.

The reference points EFSA publishes for caffeine

EFSA's 2015 opinion, produced by its Panel on Dietetic Products, Nutrition and Allergies, sets out intake levels rather than effects. Single doses of up to 200 mg of caffeine from all sources, around 3 mg per kg of body weight, do not raise safety concerns for healthy adults. Daily intakes up to 400 mg, around 5.7 mg per kg, spread across the day, do not raise safety concerns for healthy adults in the general population other than pregnant women. For pregnant and lactating women the figure is up to 200 mg per day from all sources.

Those are population-level safety reference points from a regulator, not advice about any particular food, and EFSA publishes no equivalent figures for theobromine. If you want the arithmetic of how cacao caffeine compares with other sources, the page on caffeine in ceremonial cacao works through it, and there is a separate comparison of the two methylxanthines side by side.

What has been tested in humans, and at what doses

Theobromine has been given to people in a controlled setting. Baggott and colleagues, in Psychopharmacology in 2013, ran a randomised, double-blind, placebo-controlled within-subjects trial in 84 healthy adults aged 18 to 35 from the Chicago area. Each person completed five six-hour sessions at least 48 hours apart, receiving theobromine at 250 mg, 500 mg or 1,000 mg, caffeine at 200 mg as an active control, or placebo.

The reported findings were mixed and dose-dependent. Caffeine produced the stimulant-type mood profile the researchers expected and raised blood pressure without changing heart rate. Theobromine had limited effects at 250 mg. At 500 mg and 1,000 mg, participants' "dislike" ratings rose. Theobromine raised heart rate in a dose-dependent way and did not affect blood pressure. At 1,000 mg it slowed response times on an attention task and reduced the alerting index.

The limitations matter as much as the results. The sample was restricted to light caffeine users, five or fewer cups of coffee a week, and people who did not eat large amounts of chocolate, and only Caucasian participants were accepted. The authors note the findings may not apply to frequent chocolate consumers. The genetic sub-findings were not replicated and involved multiple comparisons. It is a single trial, measuring isolated compounds in capsules, not food.

That last point is the one most often lost. A 1,000 mg theobromine dose is far above what a normal portion of dark chocolate supplies, and nothing in a study of isolated theobromine transfers automatically to a chocolate product, which arrives with fat, sugar, fibre and a few hundred other compounds.

Is cacao a stimulant: what the classification does and does not settle

Classifying a compound family is not the same as describing what a food does. Methylxanthines are stimulants as a chemical class, cacao contains two of them, and the quantities in dark chocolate have been measured repeatedly by chromatography. Everything beyond that — timing, individual response, what any of it means for a given person — is outside what these sources establish, and anyone telling you otherwise is extending the data rather than reporting it.

What is in a Chaski tube

Chaski Cacao is a 600 g tube of 77% dark chocolate buttons, with a daily dose of four buttons on the pack. The cacao is single-origin Peruvian and Ecuadorian, ground at low temperature, sweetened with coconut sugar, with Lion's Mane as a fruiting body extract and Cordyceps sinensis mycelium. There are no emulsifiers, no seed oils, no palm oil and no added cane sugar. Every batch is tested for lead, cadmium and pesticides.

Chaski does not publish a theobromine or caffeine figure, because neither has been measured in our own batches, and the figures above are commodity ranges from published analyses of other people's chocolate rather than measurements of this product. The composition is on the Chaski Cacao product page. For the terminology question rather than the chemistry one, there is a page on what ceremonial cacao means, and the rest of the library is at the Chaski guides index.

Sources

1. Sanchez JM, Foods, 2017
2. European Food Safety Authority, EFSA explains caffeine, 2015
3. Baggott MJ, Childs E, Hart AB et al., Psychopharmacology, 2013